Delivery Order SPE2DB20D9331-SPE2DB24FL1H5

Award Date 7/1/24
Potential Completion Date 7/23/24
Potential Value $5K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $14,922.24, is for the delivery of one pharmaceutical product, STELARA 130 MG/26 ML VIAL 26ML, with a period of performance through July 22, 2024. The contract is not set aside and is part of a larger indefinite delivery contract (IDC) valued up to $499,999,999 that DMS Pharmaceutical...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is for the delivery of STELARA 130 MG/26 ML VIAL 26ML. The contract has a ceiling value of $4,974.08 and an ultimate completion date of July 25, 2024. The contract is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA), a defense agency, with no set-aside designation. This contract award is part of a larger indefinite delivery contract (IDC) valued...
This federal contract award is a delivery order valued at $4,974.08, issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract provides for the delivery of STELARA 130 MG/26 ML VIAL 26ML, a biologic medication. The order is placed under a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group, valued at up to $499,999,999, which allows the DLA to issue firm fixed-price delivery orders for a...
This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $3,730.56 contract was awarded by the Defense Logistics Agency (DLA) to provide a 130 mg/26 ml vial of the pharmaceutical product STELARA. This delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which covers a wide range of pharmaceutical items...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $3,730.56, is for the delivery of STELARA 130 MG/26 ML VIAL 26ML, a specialty pharmaceutical product. The contract is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA, valued at up to $499,999,999, which enables...
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business, to provide a 130 mg/26 ml vial of the drug Stelara. The contract has a potential value of $1,243.52 and a completion date of March 20, 2024. This delivery order is part of a larger indefinite delivery contract (contract 4600082013) between DMS Pharmaceutical Group and DLA, valued at up to $4,999,999 through the end of 2025, which...
This is a firm fixed-price delivery order contract awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA). The $2,487.04 contract is for the supply of 4566528664 - STELARA 130 MG/26 ML VIAL 26ML, a specialized pharmaceutical product. The contract has a period of performance through December 12, 2024 and is not associated with any set-aside designation. DMS Pharmaceutical Group is a key supplier in the federal...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $6,312.30 contract is for the delivery of 130 mg/26 ml vials of the biologic drug Stelara, with a period of performance through February 25, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $3,606.00 contract is for the delivery of Stelara 130 mg/26 ml vials, with a final completion date of November 8, 2023. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, supporting the recurring medical supply needs of military health facilities and...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $6,217.60, is for the delivery of Stelara 130 mg/26 ml vials to support the medical supply needs of the Department of Defense (DoD). DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, for a...
  • SPE2DB20D9331
    Indefinite Delivery Contract
  • SPE2DB20D9331-SPE2DB24FL1H5
    Delivery Order

This firm-fixed price delivery order was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA) on July 1, 2024. The $4,974.08 contract is for the supply of a STELARA 130 MG/26 ML VIAL 26ML pharmaceutical product.

DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs through December 31, 2025. This IDC allows the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to fulfill the recurring medical supply needs of military health facilities worldwide. The company provides both routine and critical medications to support the diverse medical requirements of the Department of Defense healthcare system through this vehicle. This award does not have a set-aside designation.

Generated 1/9/25, 9:17 AM